Shares of BioCryst Pharmaceuticals (BCRX +3.4%) get a lift after the company reveals its BCX4208 gout drug met its primary endpoint in a Phase 2b randomized, double-blind, dose-response study. CEO Jon Stonehouse says the next big step is to find a partner for lead development for the drug that he says has a market potential of $500M.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at MarketWatch.com (Jan 14, 2015)
at Benzinga.com (Jan 14, 2015)
at CNBC.com (Jan 13, 2015)
at Benzinga.com (Jan 13, 2015)
at Benzinga.com (Dec 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs